Reshape Lifesciences (RSLS) Sets New 52-Week Low at $1.93

Shares of Reshape Lifesciences Inc (NASDAQ:RSLS) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $1.93 and last traded at $2.16, with a volume of 42257 shares trading hands. The stock had previously closed at $2.80.

RSLS has been the subject of several research reports. Zacks Investment Research raised shares of Reshape Lifesciences from a “hold” rating to a “buy” rating and set a $0.25 price objective for the company in a research note on Thursday, August 9th. LADENBURG THALM/SH SH cut shares of Reshape Lifesciences from a “buy” rating to a “neutral” rating in a research note on Friday, August 3rd. Finally, ValuEngine cut shares of Reshape Lifesciences from a “buy” rating to a “hold” rating in a research note on Tuesday, October 2nd.

The company has a market cap of $180,000.00, a PE ratio of -0.04 and a beta of 2.19.

Reshape Lifesciences (NASDAQ:RSLS) last announced its quarterly earnings data on Tuesday, August 14th. The medical device company reported ($4.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($3.01). Reshape Lifesciences had a negative net margin of 2,397.35% and a negative return on equity of 70.96%. The company had revenue of $0.65 million for the quarter. On average, analysts anticipate that Reshape Lifesciences Inc will post -2.64 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was first reported by WKRB News and is owned by of WKRB News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.wkrb13.com/2018/11/09/reshape-lifesciences-rsls-sets-new-52-week-low-at-1-93.html.

About Reshape Lifesciences (NASDAQ:RSLS)

ReShape Lifesciences Inc, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses.

Featured Story: Fiduciary

Receive News & Ratings for Reshape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reshape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply